SCHEMBL25110485

SCHEMBL25110485

COCCOCCOCCNC(=O)CCCCCCCCOC(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.49
HPGD P15428 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
EPHX2 P34913 3/20 0.43
LMNA P02545 2/20 0.42
ALDH1A1 P00352 3/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
CNR1 P21554 1/20 0.40
DEGS1 O15121 1/20 0.40
CYP3A4 P08684 1/20 0.39
RAB9A P51151 1/20 0.39
ENPP2 Q13822 1/20 0.39
LPAR1 Q92633 1/20 0.39
LPAR2 Q9HBW0 1/20 0.39
POLB P06746 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPT P10636 1/20 0.38
GLP1R P43220 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22794256 1.00 TSHR (0.49) TSHRHPGDHTTSMN1; SMN2EPHX2
SCHEMBL22790854 1.00 TSHR (0.49) TSHRHPGDHTTSMN1; SMN2EPHX2
SCHEMBL25109406 0.94 TSHR (0.53) TSHRHPGDHTTSMN1; SMN2EPHX2
SCHEMBL22794230 0.94 TSHR (0.51) TSHRHPGDHTTSMN1; SMN2LMNA
SCHEMBL22794229 0.94 TSHR (0.51) TSHRHPGDHTTSMN1; SMN2LMNA
SCHEMBL25468400 0.93 EPHX2 (0.48) TSHRHPGDHTTSMN1; SMN2EPHX2
SCHEMBL25110997 0.93 EPHX2 (0.48) TSHRHPGDHTTSMN1; SMN2EPHX2
SCHEMBL25468398 0.93 EPHX2 (0.48) TSHRHPGDHTTSMN1; SMN2EPHX2
SCHEMBL25110465 0.93 EPHX2 (0.48) TSHRHPGDHTTSMN1; SMN2EPHX2
SCHEMBL25109404 0.89 EPHX2 (0.45) SMN1; SMN2EPHX2LMNAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 TSHR 3796/4885HPGD 4236/4885HTT 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.